Wave Life Sciences Asks For 11 Million More Plan Shares As CEO Pay Ratio Hits 50:1

The annual proxy puts CEO Paul Bolno's pay at $12,277,916 and shows RA Capital, tied to a director, holding 16.76% of the stock.

Share
Wave Life Sciences Asks For 11 Million More Plan Shares As CEO Pay Ratio Hits 50:1

Wave Life Sciences' annual proxy filing, made Wednesday, put CEO Paul Bolno's total pay at $12,277,916, against $246,065 for the median employee, a disclosed ratio of 50:1. The same document asks stockholders to add 11,000,000 shares to the equity incentive plan, with one investment firm already holding the largest block of stock.

The equity plan request

Proposal 3 would increase the shares available under the Amended and Restated 2021 Equity Incentive Plan by 11,000,000. It passes if votes cast for exceed votes cast against, and abstentions have no effect.

Brokers cannot vote unvoted shares on this proposal, so uninstructed shares count as broker non-votes, which also have no effect on the result.

Stockholders will also cast a non-binding advisory vote on named executive officer pay. The proxy says the board will review the outcome but is not bound by it, and the next such vote will come at the 2027 meeting.

Who holds the shares

The ownership table is based on 197,213,583 shares outstanding on October 1, 2026. RA Capital Management beneficially owns 34,272,406 shares, or 16.76%, including 7,093,656 shares it could get through pre-funded warrants.

Peter Kolchinsky, a Wave director, is one of RA Capital's controlling persons, so the largest holder has a board seat. GSK plc, where Bolno worked before joining Wave, holds 18,245,691 shares, or 9.25%, through its subsidiary Glaxo Group Limited.

Director Ken Takanashi, an executive officer of Shin Nippon Biomedical Laboratories, is tied to a 9,800,917-share stake, or 4.97%. All current directors and executive officers as a group hold 51,278,720 shares, or 24.34%.

Bolno's own 3,049,807 shares are mostly options exercisable within 60 days of October 1, 2026. Only 19,770 are shares he holds outright.

The meeting

The annual meeting is at 11:30 a.m. Eastern on Thursday, November 12, 2026, in Cambridge, Massachusetts. Wave says it will report preliminary or final results in an 8-K within four business days.

The 11,000,000-share increase and the pay vote both go to stockholders on November 12, with RA Capital's 16.76% the largest single block among the voters.

Sources

More on Wave Life Sciences

All Wave Life Sciences (WVE) coverage →